LGND (Ligand Pharmaceuticals Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by LGND officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-07-06 | Octavio Espinoza | Chief Financial Officer | J | — | — |
| 2026-07-06 | Todd C Davis | Chief Executive Officer | J | — | — |
| 2026-07-06 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-06-18 | Stephen L Sabba | Director | MIXED | — | — |
| 2026-06-15 | Jason Haas | Director | MIXED | — | — |
| 2026-06-12 | Jason Aryeh | Director | MIXED | — | — |
| 2026-06-12 | JOHN L LAMATTINA | Director | Sell | — | — |
| 2026-06-09 | JOHN W KOZARICH | Director | A | — | — |
| 2026-06-09 | JOHN L LAMATTINA | Director | A | — | — |
| 2026-06-09 | Jason Haas | Director | A | — | — |
| 2026-06-09 | Stephen L Sabba | Director | A | — | — |
| 2026-06-09 | Martine Zimmermann | Director | MIXED | — | — |
| 2026-06-09 | Nancy Ryan Gray | Director | A | — | — |
| 2026-06-02 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-05-28 | Octavio Espinoza | Chief Financial Officer | M | — | — |
| 2026-05-14 | JOHN W KOZARICH | Director | MIXED | — | — |
| 2026-05-04 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-04-02 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-04-02 | JOHN W KOZARICH | Director | Sell | — | — |
| 2026-03-27 | Andrew Reardon | CLO & Secretary | A | — | — |
| 2026-03-27 | Todd C Davis | Chief Executive Officer | A | — | — |
| 2026-03-27 | Octavio Espinoza | Chief Financial Officer | A | — | — |
| 2026-03-25 | Stephen L Sabba | Director | Sell | — | — |
| 2026-03-13 | Octavio Espinoza | Chief Financial Officer | MIXED | — | — |
| 2026-03-06 | Octavio Espinoza | Chief Financial Officer | MIXED | — | — |
| 2026-03-06 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-03-05 | Stephen L Sabba | Director | MIXED | — | — |
| 2026-03-04 | JOHN W KOZARICH | Director | Sell | — | — |
| 2026-02-18 | Todd C Davis | Chief Executive Officer | MIXED | — | — |
| 2026-02-18 | Andrew Reardon | CLO & Secretary | MIXED | — | — |
| 2026-02-18 | Octavio Espinoza | Chief Financial Officer | MIXED | — | — |
| 2026-02-04 | JOHN W KOZARICH | Director | Sell | — | — |
| 2026-01-06 | Octavio Espinoza | Chief Financial Officer | J | — | — |
| 2026-01-06 | JOHN W KOZARICH | Director | Sell | — | — |
| 2025-12-18 | Octavio Espinoza | Chief Financial Officer | M | — | — |
| 2025-12-16 | Octavio Espinoza | Chief Financial Officer | Sell | — | — |
| 2025-12-09 | Octavio Espinoza | Chief Financial Officer | F | — | — |
| 2025-12-08 | Todd C Davis | Chief Executive Officer | G | — | — |
| 2025-12-08 | Jason Aryeh | Director | M | — | — |
| 2025-12-03 | JOHN W KOZARICH | Director | Sell | — | — |
| 2025-11-12 | Nancy Ryan Gray | Director | MIXED | — | — |
| 2025-11-12 | JOHN L LAMATTINA | Director | MIXED | — | — |
| 2025-11-05 | JOHN W KOZARICH | Director | Sell | — | — |
| 2025-10-03 | JOHN W KOZARICH | Director | Sell | — | — |
| 2025-09-24 | Martine Zimmermann | Director | F | — | — |
| 2025-09-24 | Jason Aryeh | Director | Sell | — | — |
| 2025-09-04 | JOHN W KOZARICH | Director | Sell | — | — |
| 2025-08-12 | Andrew Reardon | CLO & Secretary | F | — | — |
| 2025-08-05 | JOHN W KOZARICH | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,506,145 | — |
| — | — | 3,299,569 | — |
| — | 10%+ Owner | 2,663,034 | — |
| — | 10%+ Owner | 2,008,834 | — |
| — | 10%+ Owner | 741,627 | — |
| — | Chief Executive Officer | 417,695 | — |
| — | — | 337,896 | — |
| — | Director | 262,338 | — |
| — | — | 248,144 | — |
| — | Chief Executive Officer | 199,513 | — |
| — | — | 169,241 | — |
| — | President and COO | 162,187 | — |
| — | Director | 120,580 | — |
| — | President & COO | 50,777 | — |
| — | CLO & Secretary | 46,409 | — |
| — | Director | 42,622 | — |
| — | Director | 35,774 | — |
| — | Director | 28,820 | — |
| — | Chief Financial Officer | 27,696 | — |
| — | Director | 26,969 | — |
| — | SVP, Gen. Counsel & Secretary | 23,825 | — |
| — | VP, Finance & Strategy and CFO | 22,282 | — |
| — | VP Finance and CFO | 18,833 | — |
| — | VP, Bus. Dev. & Strategic Plan | 18,230 | — |
| — | V-P, Discovery Research | 17,042 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LGND quote page; the site-wide leaderboard is on the insider transactions hub.